- Home
- RELL vs CHRS Comparison
RELL vs CHRS Comparison
Compare RELL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RELL
- CHRS
- Stock Information
- Founded
- RELL 1947
- CHRS 2010
- Country
- RELL United States
- CHRS United States
- Employees
- RELL N/A
- CHRS N/A
- Industry
- RELL Electronic Components
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RELL Technology
- CHRS Health Care
- Exchange
- RELL Nasdaq
- CHRS Nasdaq
- Market Cap
- RELL 192.9M
- CHRS 156.0M
- IPO Year
- RELL N/A
- CHRS 2014
- Fundamental
- Price
- RELL $13.47
- CHRS $0.85
- Analyst Decision
- RELL
- CHRS Buy
- Analyst Count
- RELL 0
- CHRS 6
- Target Price
- RELL N/A
- CHRS $7.10
- AVG Volume (30 Days)
- RELL 59.2K
- CHRS 3.0M
- Earning Date
- RELL 10-09-2024
- CHRS 11-04-2024
- Dividend Yield
- RELL 1.78%
- CHRS N/A
- EPS Growth
- RELL N/A
- CHRS N/A
- EPS
- RELL N/A
- CHRS N/A
- Revenue
- RELL $197,604,000.00
- CHRS $308,134,000.00
- Revenue This Year
- RELL $14.22
- CHRS $5.18
- Revenue Next Year
- RELL $13.00
- CHRS $16.86
- P/E Ratio
- RELL N/A
- CHRS N/A
- Revenue Growth
- RELL N/A
- CHRS 69.37
- 52 Week Low
- RELL $8.08
- CHRS $0.85
- 52 Week High
- RELL $14.30
- CHRS $3.73
- Technical
- Relative Strength Index (RSI)
- RELL 63.72
- CHRS 28.71
- Support Level
- RELL $12.94
- CHRS $0.98
- Resistance Level
- RELL $13.68
- CHRS $1.01
- Average True Range (ATR)
- RELL 0.48
- CHRS 0.08
- MACD
- RELL 0.10
- CHRS -0.01
- Stochastic Oscillator
- RELL 86.05
- CHRS 0.00
About RELL Richardson Electronics Ltd.
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. Its products have applications in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. The company segments include PMT (Power and Microwave Technologies Group), Canvys, (Green Energy Solutions) GES, and Healthcare reportable segments. The company derives the majority of its revenues from the PMT segment.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.